Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
NVDQ's Cash to Debt is ranked higher than
96% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. NVDQ: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NVDQ' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.86
NVDQ's Equity to Asset is ranked higher than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NVDQ: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
NVDQ' s Equity to Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.81 Max: 0.97
Current: 0.86
-0.16
0.97
F-Score: 4
Z-Score: 10.37
M-Score: -2.42
WACC vs ROIC
-2.25%
-87.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -52.21
NVDQ's Operating margin (%) is ranked lower than
67% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. NVDQ: -52.21 )
Ranked among companies with meaningful Operating margin (%) only.
NVDQ' s Operating margin (%) Range Over the Past 10 Years
Min: -556.37  Med: -75 Max: -13.33
Current: -52.21
-556.37
-13.33
Net-margin (%) -55.05
NVDQ's Net-margin (%) is ranked lower than
66% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. NVDQ: -55.05 )
Ranked among companies with meaningful Net-margin (%) only.
NVDQ' s Net-margin (%) Range Over the Past 10 Years
Min: -507.4  Med: -84.34 Max: -48.31
Current: -55.05
-507.4
-48.31
ROE (%) -30.75
NVDQ's ROE (%) is ranked lower than
63% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. NVDQ: -30.75 )
Ranked among companies with meaningful ROE (%) only.
NVDQ' s ROE (%) Range Over the Past 10 Years
Min: -522.61  Med: -54.08 Max: -15.03
Current: -30.75
-522.61
-15.03
ROA (%) -26.38
NVDQ's ROA (%) is ranked lower than
63% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. NVDQ: -26.38 )
Ranked among companies with meaningful ROA (%) only.
NVDQ' s ROA (%) Range Over the Past 10 Years
Min: -95.19  Med: -45.04 Max: -12.4
Current: -26.38
-95.19
-12.4
ROC (Joel Greenblatt) (%) -115.50
NVDQ's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. NVDQ: -115.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVDQ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1007.74  Med: -343.68 Max: -100.5
Current: -115.5
-1007.74
-100.5
Revenue Growth (3Y)(%) 36.70
NVDQ's Revenue Growth (3Y)(%) is ranked higher than
94% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. NVDQ: 36.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVDQ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.3  Med: 25.3 Max: 143.7
Current: 36.7
-7.3
143.7
EBITDA Growth (3Y)(%) 38.60
NVDQ's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NVDQ: 38.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVDQ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.1  Med: 0.2 Max: 68.5
Current: 38.6
-31.1
68.5
EPS Growth (3Y)(%) 39.70
NVDQ's EPS Growth (3Y)(%) is ranked higher than
92% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. NVDQ: 39.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVDQ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.9  Med: 4.4 Max: 62.9
Current: 39.7
-26.9
62.9
» NVDQ's 10-Y Financials

Financials (Next Earnings Date: 2017-02-17)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

NVDQ Guru Trades in Q4 2015

Jim Simons 20,800 sh (New)
PRIMECAP Management 4,981,080 sh (+0.87%)
Chuck Royce 160,900 sh (unchged)
Ron Baron 38,000 sh (-45.71%)
Steven Cohen 143,030 sh (-85.94%)
» More
Q1 2016

NVDQ Guru Trades in Q1 2016

Steven Cohen 267,400 sh (+86.95%)
Chuck Royce 193,900 sh (+20.51%)
PRIMECAP Management 5,260,582 sh (+5.61%)
Jim Simons Sold Out
Ron Baron 31,500 sh (-17.11%)
» More
Q2 2016

NVDQ Guru Trades in Q2 2016

Ron Baron 45,000 sh (+42.86%)
PRIMECAP Management 5,420,582 sh (+3.04%)
Chuck Royce 193,900 sh (unchged)
Steven Cohen 99,600 sh (-62.75%)
» More
Q3 2016

NVDQ Guru Trades in Q3 2016

Steven Cohen 597,700 sh (+500.10%)
Ron Baron 71,000 sh (+57.78%)
PRIMECAP Management 5,686,349 sh (+4.90%)
Chuck Royce 183,400 sh (-5.42%)
» More
» Details

Insider Trades

Latest Guru Trades with NVDQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334510    SIC: 8683
Compare:NAS:NRCIA, NAS:HSKA, NAS:BEAT, NAS:LNTH, NAS:ONVO, NAS:SRDX, NAS:OXFD, NYSE:ENZ, NAS:NTRA, NAS:RDNT, NAS:TRIB, AMEX:SENS, NYSE:ARA, NYSE:NVTA, NAS:VIVO, NAS:TTOO, NAS:NEO, NAS:QDEL, NAS:CTSO, NAS:PMD » details
Traded in other countries:NDQ.Canada, NQT.Germany,
Novadaq Technologies Inc develops & commercializes medical imaging & therapeutic devices for use in the operating room. Its proprietary imaging platform can be used to visualize blood vessels, nerves & the lymphatic system during surgical procedures.

Novadaq Technologies Inc was incorporated under the Canada Business Corporations Act on April 14, 2000. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. It's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company's business activities are conducted through one segment, which consists of medical devices. Its product includes, SPY Elite, PINPOINT Endoscopic Fluorescence Imaging, FIREFLY System for Robotic Surgery, LUNA Fluorescence Angiography and CO2 HEART LASER System. The SPY Imaging System provides clinically relevant information that empowers surgeons to make informed critical decisions in the operating room. PINPOINT Endoscopic Fluorescence Imaging System combines all of the fluorescence imaging capabilities of SPY Imaging with the HD visible light imaging capabilities of a traditional endoscopic imaging system. FIREFLY system enables surgeons performing robotic surgery to benefit from fluorescence imaging, with initial use in applications ranging from urology to gynecology. LUNA fluorescence angiography enables clinicians to visually assess tissue perfusion in diabetic foot ulcers and non-healing wounds. The CO2 HEART LASER System consists of: the CO2 HEART LASER mobile console and the CO2 HEART LASER disposable hand pieces. The Company's intellectual property consists of 49 patent families representing 128 granted or allowed patents and 90 pending applications in various stages of review and prosecution.

Ratios

vs
industry
vs
history
P/B 3.48
NVDQ's P/B is ranked higher than
50% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. NVDQ: 3.48 )
Ranked among companies with meaningful P/B only.
NVDQ' s P/B Range Over the Past 10 Years
Min: 0.91  Med: 5.46 Max: 274
Current: 3.48
0.91
274
P/S 5.61
NVDQ's P/S is ranked lower than
70% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. NVDQ: 5.61 )
Ranked among companies with meaningful P/S only.
NVDQ' s P/S Range Over the Past 10 Years
Min: 1.6  Med: 12.24 Max: 297.58
Current: 5.61
1.6
297.58
EV-to-EBIT -8.59
NVDQ's EV-to-EBIT is ranked lower than
99.99% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. NVDQ: -8.59 )
Ranked among companies with meaningful EV-to-EBIT only.
NVDQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -81.5  Med: -13 Max: -0.7
Current: -8.59
-81.5
-0.7
EV-to-EBITDA -10.35
NVDQ's EV-to-EBITDA is ranked lower than
99.99% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. NVDQ: -10.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVDQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -175.2  Med: -15.8 Max: -0.8
Current: -10.35
-175.2
-0.8
Current Ratio 6.30
NVDQ's Current Ratio is ranked higher than
86% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. NVDQ: 6.30 )
Ranked among companies with meaningful Current Ratio only.
NVDQ' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 7.26 Max: 26.52
Current: 6.3
1
26.52
Quick Ratio 5.76
NVDQ's Quick Ratio is ranked higher than
87% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. NVDQ: 5.76 )
Ranked among companies with meaningful Quick Ratio only.
NVDQ' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 6.75 Max: 26.46
Current: 5.76
0.85
26.46
Days Inventory 170.27
NVDQ's Days Inventory is ranked lower than
77% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. NVDQ: 170.27 )
Ranked among companies with meaningful Days Inventory only.
NVDQ' s Days Inventory Range Over the Past 10 Years
Min: 53.17  Med: 80.39 Max: 170.27
Current: 170.27
53.17
170.27
Days Sales Outstanding 122.68
NVDQ's Days Sales Outstanding is ranked lower than
86% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. NVDQ: 122.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVDQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.76  Med: 81.23 Max: 168.34
Current: 122.68
37.76
168.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
NVDQ's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. NVDQ: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVDQ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.3  Med: -11.8 Max: -4.4
Current: -11.8
-25.3
-4.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.74
NVDQ's Price/Net Cash is ranked higher than
58% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.60 vs. NVDQ: 8.74 )
Ranked among companies with meaningful Price/Net Cash only.
NVDQ' s Price/Net Cash Range Over the Past 10 Years
Min: 5.37  Med: 8.78 Max: 63.75
Current: 8.74
5.37
63.75
Price/Net Current Asset Value 4.80
NVDQ's Price/Net Current Asset Value is ranked higher than
73% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. NVDQ: 4.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVDQ' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.31  Med: 7.05 Max: 88.33
Current: 4.8
4.31
88.33
Price/Tangible Book 4.04
NVDQ's Price/Tangible Book is ranked higher than
59% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. NVDQ: 4.04 )
Ranked among companies with meaningful Price/Tangible Book only.
NVDQ' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.62  Med: 6.4 Max: 650
Current: 4.04
2.62
650
Price/Median PS Value 0.46
NVDQ's Price/Median PS Value is ranked higher than
84% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. NVDQ: 0.46 )
Ranked among companies with meaningful Price/Median PS Value only.
NVDQ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.17  Med: 0.99 Max: 23.75
Current: 0.46
0.17
23.75
Earnings Yield (Greenblatt) (%) -11.62
NVDQ's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NVDQ: -11.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVDQ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.01  Med: 0 Max: 0
Current: -11.62
-13.01
0

More Statistics

Revenue (TTM) (Mil) $80.02
EPS (TTM) $ -0.79
Beta1.08
Short Percentage of Float10.02%
52-Week Range $7.12 - 14.36
Shares Outstanding (Mil)57.44

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 113 150 206 283
EPS ($) -0.83 -0.62 0.12 1.01
EPS w/o NRI ($) -0.83 -0.62 0.12 1.01
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NVDQ

Headlines

Articles On GuruFocus.com
Prem Watsa Increases NYT and Two Others May 15 2013 
Prem Watsa Increases Novadaq Technologies Ownership to 6.6 Pct Feb 14 2013 

More From Other Websites
NOVADAQ to Present at the 35th Annual J.P. Morgan Healthcare Conference Dec 06 2016
5 Stocks Under $10 Poised for Big Breakouts Dec 01 2016
Novadaq Technologies, Inc. :NVDQ-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 Nov 22 2016
NOVADAQ to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 22 2016
NOVADAQ Reports Third Quarter 2016 Financial Results Nov 10 2016
NOVADAQ to Present at the Canaccord Genuity Medical Technologies and Diagnostics Forum Nov 08 2016
Novadaq reports 3Q loss Nov 02 2016
Novadaq reports 3Q loss Nov 02 2016
NOVADAQ Reports Third Quarter 2016 Financial Results Nov 02 2016
NOVADAQ to Release Third Quarter 2016 Financial Results on November 2, 2016—Conference Call to... Nov 02 2016
Novadaq Technologies, Inc. breached its 50 day moving average in a Bullish Manner : NVDQ-US :... Nov 02 2016
Investor Calendar Invites You to the NOVADAQ Third Quarter 2016 Earnings Conference Call and Webcast... Nov 01 2016
NOVADAQ to Release Third Quarter 2016 Financial Results on November 2, 2016—Conference Call to... Oct 20 2016
NOVADAQ to Release Third Quarter 2016 Financial Results on November 2, 2016—Conference Call to... Oct 20 2016
NOVADAQ to Host Analyst and Investor Day on November 14, 2016 Oct 05 2016
NOVADAQ to Host Analyst and Investor Day on November 14, 2016 Oct 05 2016
Novadaq Technologies, Inc. – Value Analysis (NASDAQ:NVDQ) : October 4, 2016 Oct 04 2016
Novadaq Technologies, Inc. breached its 50 day moving average in a Bullish Manner : NVDQ-US :... Oct 03 2016
NOVADAQ Announces Appointment of Karen A. Licitra to its Board of Directors Sep 06 2016
NOVADAQ to Present at the 2016 Morgan Stanley Global Healthcare Conference Aug 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)